CA2722256A1 - 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors - Google Patents

5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors Download PDF

Info

Publication number
CA2722256A1
CA2722256A1 CA2722256A CA2722256A CA2722256A1 CA 2722256 A1 CA2722256 A1 CA 2722256A1 CA 2722256 A CA2722256 A CA 2722256A CA 2722256 A CA2722256 A CA 2722256A CA 2722256 A1 CA2722256 A1 CA 2722256A1
Authority
CA
Canada
Prior art keywords
formula
compound
methyl
pyrazol
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2722256A
Other languages
English (en)
French (fr)
Inventor
Antoni Torrens Jover
Maria Rosa Cuberes-Altisent
Maria Jose Pretel Sanchez
Maria Magdalena Bordas Gelabert
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Publication of CA2722256A1 publication Critical patent/CA2722256A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2722256A 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors Abandoned CA2722256A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08384005A EP2113501A1 (en) 2008-04-25 2008-04-25 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP08384005.8 2008-04-25
PCT/EP2009/055065 WO2009130331A1 (en) 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors

Publications (1)

Publication Number Publication Date
CA2722256A1 true CA2722256A1 (en) 2009-10-29

Family

ID=39739580

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2722256A Abandoned CA2722256A1 (en) 2008-04-25 2009-04-27 5-methyl-1-(naphthalen-2-yl)-1h-pyrazoles useful as sigma receptor inhibitors

Country Status (11)

Country Link
US (1) US8492425B2 (enExample)
EP (2) EP2113501A1 (enExample)
JP (1) JP2011518811A (enExample)
KR (1) KR20110006697A (enExample)
CN (1) CN102066333A (enExample)
AU (1) AU2009239906A1 (enExample)
BR (1) BRPI0910679A2 (enExample)
CA (1) CA2722256A1 (enExample)
MX (1) MX2010011674A (enExample)
RU (1) RU2010147918A (enExample)
WO (1) WO2009130331A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2361904A1 (en) * 2010-02-04 2011-08-31 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride and crystalline forms thereof
US20130143884A1 (en) * 2009-11-25 2013-06-06 Maria Rosa Cuberes-Altisent 4-[2-[ [5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl] morpholine salts
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
RS55046B1 (sr) * 2010-02-04 2016-12-30 Esteve Labor Dr 4-[2-[[5-metil-1-(2-naftalenil)-1h-pirazol-3-il]oksi]etil]morfolin hidrohlorid i solvati
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2395003A1 (en) 2010-05-27 2011-12-14 Laboratorios Del. Dr. Esteve, S.A. Pyrazole compounds as sigma receptor inhibitors
EP2418192A1 (en) * 2010-07-30 2012-02-15 Esteve Química, S.A. Intermediates for the preparation of 1-aryl-pyrazol-3-one compounds useful as sigma receptors inhibitors
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2460519A1 (en) 2010-12-03 2012-06-06 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in bone cancer pain
EP2460804A1 (en) * 2010-12-03 2012-06-06 Laboratorios Del Dr. Esteve, S.A. 5-methyl-1-(naphthalen-2-yl)-1h-pyrazole derivatives and their use in potentiating the effect of opioid analgesics
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
WO2016019288A1 (en) 2014-08-01 2016-02-04 Smart Billiard Lighting LLC Billiard table lighting and game play monitor
MA41177A (fr) * 2014-12-15 2017-10-24 Esteve Labor Dr Utilisation de ligands des récepteurs sigma dans l'arthrose
US12345406B2 (en) 2022-02-09 2025-07-01 Blake Martin Interactive LED system for enhancing billiard gameplay

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9824310D0 (en) 1998-11-05 1998-12-30 Univ London Activators of soluble guanylate cyclase
EP2325174A1 (en) 2004-08-27 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Sigma receptor inhibitors
EP1634872A1 (en) * 2004-08-27 2006-03-15 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP1829875A1 (en) * 2006-03-01 2007-09-05 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
US8202872B2 (en) 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors

Also Published As

Publication number Publication date
MX2010011674A (es) 2010-11-25
BRPI0910679A2 (pt) 2015-09-29
KR20110006697A (ko) 2011-01-20
RU2010147918A (ru) 2012-05-27
CN102066333A (zh) 2011-05-18
WO2009130331A1 (en) 2009-10-29
US8492425B2 (en) 2013-07-23
EP2113501A1 (en) 2009-11-04
JP2011518811A (ja) 2011-06-30
US20110118253A1 (en) 2011-05-19
AU2009239906A1 (en) 2009-10-29
EP2285781A1 (en) 2011-02-23

Similar Documents

Publication Publication Date Title
US8492425B2 (en) 5-methyl-1-(naphthalen-2-yl)-1H-pyrazoles useful as sigma receptor inhibitors
DE60219292T2 (de) Pyrazolderivate zur behandlung von hiv
CA2576144C (en) Sigma receptor inhibitors
US8202872B2 (en) Pyrazole derivatives as sigma receptor inhibitors
CA2241787C (en) Substituted aza- and diazacycloheptane and cyclooctane compounds and their use
AU2007316605B2 (en) 1,2,4-triazole derivatives as sigma receptor inhibitors
DE69428142T2 (de) Quinolin- oder Quinazolinderivate, deren Herstellung und Verwendung
US8314096B2 (en) Sigma receptor inhibitors
CA2129146A1 (en) Imidazole, triazole and tetrazole derivatives
CA2595569C (en) Substituted triazole derivatives as oxytocin antagonists
WO2007091152A1 (en) Triazolopyridine compounds
US8138186B2 (en) Pyrazole derivatives as sigma receptors antagonists
AU2009239889B2 (en) Process for the preparation of naphthalen-2-yl-pyrazol-3-one intermediates useful in the synthesis of sigma receptor inhibitors
EP2066648B1 (en) Substituted dimethylcyclobutyl compounds, their preparation and use in medicaments
FI94049C (fi) Menetelmä terapeuttisesti käyttökelpoisten N-(3-hydroksi-4-piperidinyyli)bentsamidien valmistamiseksi
KR20080067355A (ko) 염증 치료에 유용한 피라졸
WO2006056848A1 (en) Octahydropyrrolo[3,4-c]pyrrole derivatives
EP1829875A1 (en) Pyrazole derivatives as sigma receptor inhibitors
KR20080032206A (ko) Ｃｂ１ 조절제로서의 피라졸 유도체
EP1829867A1 (en) Imidazole compounds having pharmaceutical activity towards the sigma receptor
EP2468728A1 (en) 2-(1-phenyl-4,5,6,7-tetrahydro-1H-indazol-4-YL)ethylamine derivatives useful as sigma receptor inhibitors
CA3125847A1 (en) Process for making biologically active compounds and intermediates thereof
JPH01190669A (ja) ４−置換された３−メチル−１−アリール−５−アミノ−ピラゾール類の製造方法
HK1106532B (en) Sigma receptor inhibitors
HK1159078A (en) Sigma receptor inhibitors

Legal Events

Date Code Title Description
FZDE Dead

Effective date: 20150428